Cannabinoid transmission and reward-related events

Neurobiology of Disease

Volumn 5, Issue 6, 1998, Pages 502-533

  Gardner, Eliot L ^a   Vorel, S Robert ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Addiction; Brain stimulation; Cannabinoid; Cannabis; Dependence; Dopamine; Drug abuse; ICSS; Marijuana; Medial forebrain bundle; Microdialysis; Nucleus accumbens; Place preference; Reinforcement; Reward; Ventral tegmental area

Indexed keywords

CANNABINOID; CANNABINOID RECEPTOR; CANNABIS; DOPAMINE; DOPAMINE RECEPTOR; DRONABINOL; GUANINE NUCLEOTIDE BINDING PROTEIN; OPIATE PEPTIDE;

ARTICLE; DRUG DEPENDENCE; DRUG PREFERENCE; DYSPHORIA; ELECTROSTIMULATION; EUPHORIA; FOREBRAIN; GENETIC VARIABILITY; GLOBUS PALLIDUS; HUMAN; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; PLACE PREFERENCE; PRIORITY JOURNAL; REINFORCEMENT; REWARD; TASTE PREFERENCE; VENTRAL TEGMENTUM; WITHDRAWAL SYNDROME;

EID: 0032461050     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1006/nbdi.1998.0219     Document Type: Article

References (314)

1. Marijuana/Cannabinoids: Neurobiology and Neurophysiology. 1992;CRC Press, Boca Raton.
2. Pertwee R. Cannabinoid Receptors. 1995;Academic Press, London.
3. Mechoulam R., Ben Shabat S., Hanus L., Fride E., Vogel Z., Bayewitch M., Sulcova A. E. Endogenous cannabinoid ligands - Chemical and biological studies. J. Lipid Mediators Cell Signalling. 14:1996;45-49.
4. Devane W. A., Dysarz F. A., Johnson M. R., Melvin L. S., Howlett A. C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:1988;605-613.
5. Johnson M., Devane W., Howlett A., Melvin L., Milne G. Structural studies leading to the discovery of a cannabinoid binding site. Natl. Inst. Drug Abuse Res. Monogr. Ser. 90:1988;129-135.
6. Howlett A. C., Johnson M. R., Melvin L. S., Milne G. M. Nonclassical cannabinoid analgetics inhibit adenylate cyclase: Development of a cannabinoid receptor model. Mol. Pharmacol. 33:1988;297-302.
7. Bidaut-Russell M., Devane W. A., Howlett A. C. Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain. J. Neurochem. 55:1990;21-26.
8. Howlett A. C., Bidaut-Russell M., Devane W. A., Melvin L. S., Johnson M. R., Herkenham M. The cannabinoid receptor: Biochemical, anatomical, and behavioral characterization. Trends Neurosci. 13:1990;420-423.
9. Howlett A. C., Champion-Dorow T. M., McMahon I. L., Westlake T. M. The cannabinoid receptor: Biochemical and cellular properties in neuroblastoma cells. Pharmacol. Biochem. Behav. 40:1991;565-569.
10. Martin B. R., Welch S. P., Abood M. Progress toward understanding the cannabinoid receptor and its second messenger system. Adv. Pharmacol. 25:1994;341-397.
11. Matsuda L. A., Lolait S. J., Brownstein M. J., Young A. C., Bonner T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
12. Munro S., Thomas K. L., Abu S. M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
13. Reisine T., Brownstein M. J. Opioid and cannabinoid receptors. Curr. Opin. Neurobiol. 4:1994;406-412.
14. Herkenham M., Lynn A. B., Little M. D., Johnson M. R., Melvin L. S., de Costa B. R., Rice K. C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA. 87:1990;1932-1936.
15. Herkenham M., Lynn A. B., Johnson M. R., Melvin L. S., de Costa B. R., Rice K. C. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J. Neurosci. 11:1991;563-583.
16. Shire D., Carillon C., Kaghad M., Calandra B., Rinaldi-Carmona M., Le Fur G., Caput D., Ferrara P. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J. Biol. Chem. 270:1995;3726-3731.
17. Rinaldi-Carmona M., Calandra B., Shire D., Bouaboula M., Oustric D., Barth F., Casellas P., Ferrara P., Le Fur G. Characterization of two cloned human CB1 cannabinoid receptor isoforms. J. Pharmacol. Exp. Ther. 278:1996;871-878.
18. Makriyannis A. Probes for the cannabinoid sites of action. Natl. Inst. Drug Abuse Res. Monogr. Ser. 134:1993;253-267.
19. Melvin L. S., Milne G. M., Johnson M. R., Subramaniam B., Wilken G. H., Howlett A. C. Structure-activity relationships for receptor-binding and analgesic activity: Studies of bicyclic cannabinoid analogs. Mol. Pharmacol. 44:1993;1008-1015.
20. Melvin L. S., Milne G. M., Johnson M. R., Wilken G. H., Howlett A. C. Structure-activity relationships defining the ACD-tricyclic cannabinoids: Cannabinoid receptor binding and analgesic activity. Drug Design Disc. 13:1995;155-166.
21. Tius M. A., Hill W. A., Zou X. L., Busch-Petersen J., Kawatami J. K., Fernandez-Garcia M. C., Drake D. J., Abadji V., Makriyannis A. Classical/non-classical cannabinoid hybrids: Stereochemical requirements for the southern hydroxylalkyl chain. Life Sci. 56:1995;2007-2012.
22. Xie X. Q., Melvin L. S., Makriyannis A. The conformational properties of the highly selective cannabinoid receptor ligand CP-55,940. J. Biol. Chem. 271:1996;10640-10647.
23. Xie X. Q., Eissenstat M., Makriyannis A. Common cannabimimetic pharmacophoric requirements between aminoalkyl indoles and classical cannabinoids. Life Sci. 56:1995;1963-1970.
24. Eissenstat M. A., Bell M. R., D'Ambra T. E., Alexander E. J., Daum S. J., Ackerman J. H., Gruett M. D., Kumar V., Estep K. G., Olefirowicz E. M. Aminoalkylindoles: Structure-activity relationships of novel cannabinoid mimetics. J. Med. Chem. 38:1995;3094-3105.
25. Bloom A. S., Edgemond W. S., Moldvan J. C. Nonclassical and endogenous cannabinoids: Effects on the ordering of brain membrane. Neurochem. Res. 22:1997;563-568.
26. Ryan W., Singer M., Razdan R. K., Compton D. R., Martin B. R. A novel class of potent tetrahydrocannabinols (THCs): 2′-Yne-delta 8 and delta 9-THCs. Life Sci. 56:1995;2013-2020.
27. Showalter V. M., Compton D. R., Martin B. R., Abood M. E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. 278:1996;989-999.
28. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., Caput D. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
29. Rinaldi-Carmona M., Barth F., Heaulme M., Alonso R., Shire D., Congy C., Soubrié P., Brelière J. C., Le Fur G. Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci. 56:1995;1941-1947.
30. Barth, F. Rinaldi-Carmona, M. Millan, J. Derocq, J.-M. Bouaboula, M. Casellas, P. Congy, C. Oustric, D. Sarran, M. Calandra, B. Portier, M. Shire, D. Brelière, C. Le Fur, G. 1997, SR 144528, a potent and selective antagonist of the CB2 receptor.
31. Devane W. A., Hanus L., Breuer A., Pertwee R. G., Stevenson L. A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
32. Sugiura T., Kondo S., Sukagawa A., Tonegawa T., Nakane S., Yamashita A., Waku K. N. J. Lipid Mediators Cell Signalling. 14:1996;51-56.
33. Mechoulam R., Ben Shabat S., Hanus L., Ligumsky M., Kaminski N. E., Schatz A. R., Gopher A., Almog S., Martin B. R., Compton D. R. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50:1995;83-90.
34. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., Waku K. 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215:1995;89-97.
35. Childers S. R., Sexton T., Roy M. B. Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochem. Pharmacol. 47:1994;711-715.
36. Devane W. A., Axelrod J. Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes. Proc. Natl. Acad. Sci. USA. 91:1994;6698-6701.
37. Koutek B., Prestwich G. D., Howlett A. C., Chin S. A., Salehani D., Akhavan N., Deutsch D. G. Inhibitors of arachidonoyl ethanolamide hydrolysis. Biol. Chem. 269:1994;22937-22940.
38. Hillard C. J., Edgemond W. S., Campbell W. B. Characterization of ligand binding to the cannabinoid receptor of rat brain membranes using a novel method: Application to anandamide. J. Neurochem. 64:1995;677-683.
39. Desarnaud F., Cadas H., Piomelli D. Anandamide amidohydrolase activity in rat brain microsomes: Identification and partial characterization. J. Biol. Chem. 270:1995;6030-6035.
40. Fride E., Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist anandamide, a brain constituent. Eur. J. Pharmacol. 231:1993;447-454.
41. Crawley J. N., Corwin R. L., Robinson J. K., Felder C. C., Devane W. A., Axelrod J. Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacol. Biochem. Behav. 46:1993;967-972.
42. Smith P. B., Compton D. R., Welch S. P., Razdan R. K., Mechoulam R., Martin B. R. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther. 270:1994;219-227.
43. Howlett A. C. Pharmacology of cannabinoid receptors. Annu. Rev. Pharmacol. Toxicol. 35:1995;607-634.
44. Mechoulam R., Hanus L., Martin B. R. Search for endogenous ligands of the cannabinoid receptor. Biochem. Pharmacol. 48:1994;1537-1544.
45. Barg J., Fride E., Hanus L., Levy R., Matus-Leibovitch N., Heldman E., Bayewitch M., Mechoulam R., Vogel Z. Cannabimimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. Eur. J. Pharmacol. 287:1995;145-152.
46. Evans D. M., Lake J. T., Johnson M. R., Howlett A. C. Endogenous cannabinoid receptor binding activity released from rat brain slices by depolarization. J. Pharmacol. Exp. Ther. 268:1994;1271-1277.
47. Mechoulam R. The pharmacohistory of cannabis sativa. Mechoulam R. Cannabinoids as Therapeutic Agents. 1986;1-16 CRC Press, Boca Raton.
48. Kozel N. J., Adams E. H. Epidemiology of drug abuse: An overview. Science. 234:1986;970-974.
49. Goldstein A., Kalant H. Drug policy: Striking the right balance. Science. 249:1990;1513-1521.
50. MacCoun R., Reuter P. Interpreting Dutch cannabis policy: Reasoning by analogy in the legalization debate. Science. 278:1997;47-52.
51. Kleber H. D. Introduction - Cocaine abuse: Historical, epidemiological, and psychological perspectives. J. Clin. Psychiat. 49:1988;3-6.
52. Crowley T. J., Macdonald M. J., Whitmore E. A., Mikulich S. K. Cannabis dependence, withdrawal, and reinforcing effects among adolescents with conduct symptoms and substance use disorders. Drug Alcohol Depend. 1998.
53. Anthony J. C., Warner L. A., Kessler R. C. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances and inhalants: Basic findings from National Comorbidity Study. Exp. Clin. Psychopharmacol. 2:1994;244-268.
54. Hall, W. Solowij, N. Lemon, J. 1994, The Health and Psychological Consequences of Cannabis Use, Australian Govt. Publ. Service, Canberra.
55. Hollister L. E. Health aspects of cannabis. Pharmacol. Rev. 38:1986;1-20.
56. Pope H. G. Jr., Yurgelun-Todd D. The residual cognitive effects of heavy marijuana use in college students. J. Am. Med. Assoc. 275:1996;521-527.
57. Killam K. F., Olds J., Sinclair J. Further studies on the effects of centrally acting drugs on self-stimulation. J. Pharmacol. Exp. Ther. 119:1957;157.
58. Gardner E. L. Brain reward mechanisms. Lowinson J. H., Ruiz P., Millman R. B., Langrod J. G. Substance Abuse: A Comprehensive Textbook. 1997;51-85 Williams & Wilkins, Baltimore.
59. Kornetsky C. Brain-stimulation reward: A model for the neuronal bases for drug-induced euphoria. Natl. Inst. Drug Abuse Res. Monogr. Ser. 62:1985;30-50.
60. Wise R. A. Action of drugs of abuse on brain reward systems. Pharmacol. Biochem. Behav. 13:1980;213-223.
61. Wise R. A. Neural mechanisms of the reinforcing action of cocaine. Natl. Inst. Drug Abuse Res. Monogr. Ser. 50:1984;15-33.
62. Di Chiara G., Imperato A. Preferential stimulation of dopamine release in the nucleus accumbens by opiates, alcohol, and barbiturates: Studies with transcerebral dialysis in freely moving rats. Ann. N. Y. Acad. Sci. 473:1986;367-381.
63. Imperato A., Mulas A., Di Chiara G. Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur. J. Pharmacol. 132:1986;337-338.
64. Wise R. A., Rompré P.-P. Brain dopamine and reward. Annu. Rev. Psychol. 40:1989;191-225.
65. Carboni E., Imperato A., Perezzani L., Di Chiara G. Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely-moving rats. Neuroscience. 28:1989;653-661.
66. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. USA. 85:1988;5274-5278.
67. Bozarth M. A., Wise R. A. Intracranial self-administration of morphine into the ventral tegmental area of rats. Life Sci. 28:1981;551-555.
68. Goeders N. E., Smith J. E. Cortical dopaminergic involvement in cocaine reinforcement. Science. 221:1983;773-775.
69. Goeders N. E., Lane J. D., Smith J. E. Self-administration of methionine enkephalin into the nucleus accumbens. Pharmacol. Biochem. Behav. 20:1984;451-455.
70. Hoebel B. G., Monaco A. P., Hernandez L., Aulisi E. F., Stanley B. G., Lenard L. Self-injection of amphetamine directly into the brain. Psychopharmacology. 81:1983;158-163.
71. Phillips A. G., LePiane F. G. Reinforcing effects of morphine microinjection into the ventral tegmental area. Pharmacol. Biochem. Behav. 12:1980;965-968.
72. Bozarth M. A., Wise R. A. Heroin reward is dependent on a dopaminergic substrate. Life Sci. 29:1981;1881-1886.
73. Spyraki C., Fibiger H. C., Phillips A. G. Attenuation of heroin reward in rats by disruption of the mesolimbic dopamine system. Psychopharmacology. 79:1983;278-283.
74. Gardner E. L. Neurobiology of drug addiction/dependency. Seminars in the Neurosciences. 1993;Academic Press, London.
75. Gardner E. L., David J. The neurobiology of chemical addiction. Getting Hooked: Rationality and the Addictions. 1998;Cambridge Univ. Press, New York.
76. Wise R. A. Neurobiology of addiction. Curr. Opin. Neurobiol. 6:1996;243-251.
77. Nestler E. J. Molecular mechanisms of drug addiction in the mesolimbic dopamine pathway. Semin. Neurosci. 5:1993;369-376.
78. Self D. W., Nestler E. J. Molecular mechanisms of drug reinforcement and addiction. Annu. Rev. Neurosci. 18:1995;463-495.
79. Nestler E. J., Berhow M. T., Brodkin E. S. Molecular mechanisms of drug addiction: Adaptations in signal transduction pathways. Mol. Psychiatr. 1:1996;190-199.
80. Blum K., Cull J. G., Braverman E. R., Comings D. E. Reward deficiency syndrome. Am. Sci. 84:1996;132-145.
81. Koob G. F., Le Moal M. Drug abuse: Hedonic homeostatic dysregulation. Science. 278:1997;52-58.
82. Gardner E. L., Lowinson J. H. Drug craving and positive/negative hedonic brain substrates activated by addicting drugs. Semin. Neurosci. 5:1993;359-368.
83. Di Chiara G. The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend. 38:1995;95-137.
84. Schultz W., Dayan P., Montague P. R. A neural substrate of prediction and reward. Science. 275:1997;1593-1599.
85. Wickelgren I. Getting the brain's attention. Science. 278:1997;35-37.
86. Kornetsky C., Brain G. Brain-stimulation reward: A model for the study of the rewarding effects of abused drugs. Natl. Inst. Drug Abuse Res. Monogr. Ser. 124:1992;73-93.
87. Kornetsky C., Duvauchelle C. Dopamine, a common substrate for the rewarding effects of brain stimulation reward, cocaine, and morphine. Natl. Inst. Drug Abuse Res. Monogr. Ser. 145:1994;19-39.
88. Shizgal P. Neural basis of utility estimation. Curr. Opin. Neurobiol. 7:1997;198-208.
89. Wise R. A. Addictive drugs and brain stimulation reward. Annu. Rev. Neurosci. 19:1996;319-340.
90. Gardner E. L., Chen J., Paredes W. Overview of chemical sampling techniques. J. Neurosci. Methods. 48:1993;173-197.
91. Bozarth M. A. Methods of Assessing the Reinforcing Properties of Abused Drugs. 1987;Springer-Verlag, New York.
92. 9. Psychopharmacology. 96:1988;142-144.
93. Gardner E. L., Lowinson J. H. Marijuana's interaction with brain reward systems: Update 1991. Pharmacol. Biochem. Behav. 40:1991;571-580.
94. Gardner E. L. Cannabinoid interaction with brain reward systems - The neurobiological basis of cannabinoid abuse. Murphy L. L., Bartke A. Marijuana/Cannabinoids: Neurobiology and Neurophysiology. 1992;275-335 CRC Press, New York.
95. 9. Soc. Neurosci. Abstr. 21:1995;177.
96. 9. Life Sci. (Pharmacol. Lett.). 58:1996;PL365-PL372.
97. George F. R., Goldberg S. R. Genetic approaches to the analysis of addiction processes. Trends Pharmacol. Sci. 10:1989;78-83.
98. Guitart X., Beitner-Johnson D., Marby D. W., Kosten T. A., Nestler E. J. Fischer and Lewis rat strains differ in basal levels of neurofilament proteins and their regulation by chronic morphine in the mesolimbic dopamine system. Synapse. 12:1992;242-253.
99. Kosten T. A., Miserendino M. J., Chi S., Nestler E. J. Fischer and Lewis rat strains show differential cocaine effects in conditioned place preference and behavioral sensitization but not in locomotor activity or conditioned taste aversion. J. Pharmacol. Exp. Ther. 269:1994;137-144.
100. Ng Cheong Ton J. M., Gardner E. L. Effects of delta-9-tetrahydrocannabinol on dopamine release in the brain: Intracranial dialysis experiments. Soc. Neurosci. Abstr. 12:1986;135.
101. 9. Brain Res. 451:1988;59-68.
102. 9. Soc. Neurosci. Abstr. 15:1989;1096.
103. 9. Eur. J. Pharmacol. 190:1990;259-262.
104. 9. Psychopharmacology. 102:1990;156-162.
105. 9. Chesher G., Consroe P., Musty R. Marijuana: An International Research Report. 1988;405-408 Australian Govt. Publ. Service, Canberra.
106. 1. Science. 276:1997;2048-2050.
107. Pontieri F. E., Tanda G., Di Chiara G. Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the "shell" as compared with the "core" of the rat nucleus accumbens. Proc. Natl. Acad. Sci. USA. 92:1995;12304-12308.
108. Johnson P. I., Goodman J. B., Condon R., Stellar J. R. Reward shifts and motor responses following microinjections of opiate-specific agonists into either the core or shell of the nucleus accumbens. Psychopharmacology. 120:1995;195-202.
109. Carlezon W. A. Jr., Wise R. A. Rewarding actions of phencyclidine and related drugs in nucleus accumbens shell and frontal cortex. J. Neurosci. 16:1996;3112-3122.
110. Carlezon W. A. Jr., Wise R. A. Microinjections of phencyclidine (PCP) and related drugs into nucleus accumbens shell potentiate medial forebrain bundle brain stimulation reward. Psychopharmacology. 128:1996;413-420.
111. Castañeda E., Moss D. E., Oddie S. D., Whishaw I. Q. THC does not affect striatal dopamine release: Microdialysis in freely moving rats. Pharmacol. Biochem. Behav. 40:1991;587-591.
112. Banerjee S. P., Snyder S. H., Mechoulam R. Cannabinoids: Influence on neurotransmitter uptake in rat brain synaptosomes. J. Pharmacol. Exp. Ther. 194:1975;74-81.
113. 9d. Psychopharmacology. 54:1977;177-182.
114. 9. Psychopharmacology. 57:1978;243-248.
115. 9. Psychopharmacology. 67:1980;215-219.
116. 9. J. Pharmacol. Exp. Ther. 221:1982;97-103.
117. Poddar M. K., Dewey W. L. Effects of cannabinoids on catecholamine uptake and release in hypothalamic and striatal synaptosomes. J. Pharmacol. Exp. Ther. 214:1980;63-67.
118. 9. Subst. Alcohol Actions/Misuse. 5:1984;201-210.
119. 9. Brain Res. Bull. 14:1985;85-90.
120. 9. Pharmacol. Biochem. Behav. 33:1989;397-400.
121. 9. Brain Res. 366:1986;405-407.
122. 9. Neuropsychopharmacology. 16:1997;426-432.
123. 9. Synapse. 28:1998;21-26.
124. Rodríguez de Fonseca F., Fernández-Ruiz J. J., Murphy L. L., Cebeira M., Steger R. W., Bartke A., Ramos J. A. Acute effects of δ-9-tetrahydrocannabinol on dopaminergic activity in several rat brain areas. Pharmacol. Biochem. Behav. 42:1992;269-275.
125. 9. Pharmacol. Biochem. Behav. 45:1993;291-298.
126. 9. J. Neural Transm. 92:1993;81-95.
127. 9. Behav. Brain Res. 57:1993;37-46.
128. Romero J., de Miguel R., García-Palomero E., Fernández-Ruiz J. J., Ramos J. A. Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function. Brain Res. 694:1995;223-232.
129. Romero J., García L., Cebeira M., Zadrozny D., Fernández-Ruiz J. J., Ramos J. A. The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: Role of nigrostriatal dopaminergic neurons. Life Sci. 56:1995;2033-2040.
130. Gysling K., Wang R. Y. Morphine-induced activation of A10 dopamine neurons in the rat. Brain Res. 277:1983;119-127.
131. Grenhoff J., Aston-Jones G., Svensson T. H. Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta Physiol. Scand. 128:1986;351-358.
132. Gifford A. N., Gardner E. L., Ashby C. R. Jr. The effect of intravenous administration of delta-9-tetrahydrocannabinol on the activity of A10 dopamine neurons recorded in vivo in anesthetized rats. Neuropsychobiology. 36:1997;96-99.
133. 9. Neurosci. Lett. 226:1997;159-162.
134. Miller A. S., Walker J. M. Effects of a cannabinoid on spontaneous and evoked neuronal activity in the substantia nigra pars reticulata. Eur. J. Pharmacol. 279:1995;179-185.
135. Tersigni T. J., Rosenberg H. C. Local pressure application of cannabinoid agonists increases spontaneous activity of rat substantia nigra pars reticulata neurons without affecting response to iontophoretically-applied GABA. Brain Res. 733:1996;184-192.
136. Herkenham M., Lynn A. B., De Costa B. R., Richfield E. K. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res. 547:1991;267-274.
137. Jansen E. M., Haycock D. A., Ward S. A., Seybold V. S. Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles. Brain Res. 575:1992;93-102.
138. Mailleux P., Vanderhaeghen J. J. Distribution of neuronal cannabinoid receptor in the adult rat brain: A comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience. 48:1992;655-668.
139. Matsuda L. A., Bonner T. I., Lolait S. J. Localization of cannabinoid receptor mRNA in rat brain. J. Comp. Neurol. 327:1993;535-550.
140. Rodríguez de Fonseca F., Cebeira M., Hernández M. L., Ramos J. A., Fernández-Ruiz J. J. Changes in brain dopaminergic indices induced by perinatal exposure to cannabinoids in rats. Dev. Brain Res. 51:1990;237-240.
141. Rodríguez de Fonseca F., Cebeira M., Fernández-Ruiz J. J., Navarro M., Ramos J. A. Effects of pre- and perinatal exposure to hashish extracts on the ontogeny of brain dopaminergic neurons. Neuroscience. 43:1991;713-723.
142. Rodríguez de Fonseca F., Hernández M. L., de Miguel R., Fernández-Ruiz J. J., Ramos J. A. Early changes in the development of dopaminergic neurotransmission after maternal exposure to cannabinoids. Pharmacol. Biochem. Behav. 41:1992;469-474.
143. Navarro M., Rodríguez de Fonseca F., Hernández M. L., Ramos J. A., Fernández-Ruiz J. J. Motor behavior and nigrostriatal dopaminergic activity in adult rats perinatally exposed to cannabinoids. Pharmacol. Biochem. Behav. 47:1994;47-58.
144. Navarro M., de Miguel R., Rodríguez de Fonseca F., Ramos J. A., Fernández-Ruiz J. J. Prenatal cannabinoid exposure modifies the sociosexual approach behavior and the mesolimbic dopaminergic activity of adult male rats. Behav. Brain Res. 75:1996;91-98.
145. Fernández-Ruiz J. J., Rodríguez de Fonseca F., Navarro M., Ramos J. A. Maternal cannabinoid exposure and brain development: Changes in the ontogeny of dopaminergic neurons. Murphy L. L., Bartke A. Marijuana/Cannabinoids: Neurobiology and Neurophysiology. 1992;119-164 CRC Press, New York.
146. Navarro M., Rubio P., Rodríguez de Fonseca F. Behavioural consequences of maternal exposure to natural cannabinoids in rats. Psychopharmacology. 122:1995;1-14.
147. Garcia L., de Miguel R., Ramos J. A., Fernández-Ruiz J. J. Perinatal delta-9-tetrahydrocannabinol exposure in rats modifies the responsiveness of midbrain dopaminergic neurons in adulthood to a variety of challenges with dopaminergic drugs. Drug Alcohol Depend. 42:1996;155-166.
148. Bonnin A., de Miguel R., Rodríguez-Manzaneque J. C., Fernández-Ruiz J. J., Santos A., Ramos J. A. Changes in tyrosine hydroxylase gene expression in mesencephalic catecholaminergic neurons of immature and adult male rats perinatally exposed to cannabinoids. Dev. Brain Res. 81:1994;147-150.
149. Bonnin A., de Miguel R., Castro J. G., Ramos J. A., Fernández-Ruiz J. J. Effects of perinatal exposure to delta-9-tetrahydrocannabinol on the fetal and early postnatal development of tyrosine hydroxylase-containing neurons in rat brain. J. Mol. Neurosci. 7:1996;291-308.
150. Walters D. E., Carr L. A. Changes in brain catecholamine mechanisms following perinatal exposure to marijuana. Pharmacol. Biochem. Behav. 25:1986;763-778.
151. Imperato A., Mele A., Scrocco M. G., Puglisi-Allegra S. Chronic cocaine alters limbic extracellular dopamine: Neurochemical basis for addiction. Eur. J. Pharmacol. 212:1992;299-300.
152. Parsons L. H., Smith A. D., Justice J. B. Jr. Basal extracellular dopamine is decreased in the rat nucleus accumbens during abstinence from chronic cocaine. Synapse. 9:1991;60-65.
153. Robertson M. W., Leslie C. A., Bennett J. P. Apparent synaptic dopamine deficiency induced by withdrawal from chronic cocaine treatment. Brain Res. 538:1991;337-339.
154. Pothos E., Rada P., Mark G. P., Hoebel B. G. Dopamine microdialysis in the nucleus accumbens during acute and chronic morphine, naloxone-precipitated withdrawal and clonidine treatment. Brain Res. 566:1991;348-350.
155. Crippens D., Robinson T. E. Withdrawal from morphine or amphetamine: Different effects on dopamine in the ventral-medial striatum studied with microdialysis. Brain Res. 650:1994;56-62.
156. Rossetti Z. L., Hmaidan Y., Gessa G. L. Marked inhibition of mesolimbic dopamine release: A common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats. Eur. J. Pharmacol. 221:1992;227-234.
157. Acquas E., Di Chiara G. Depression of mesolimbic dopamine transmission and sensitization to morphine during opiate abstinence. J. Neurochem. 58:1992;1620-1625.
158. Spanagel R., Almeida O. F., Bartl C., Shippenberg T. S. Endogenous kappa-opioid systems in opiate withdrawal: Role in aversion and accompanying changes in mesolimbic dopamine release. Psychopharmacology. 115:1994;121-127.
159. Kokkinidis L., Zacharko R. M., Predy P. A. Post-amphetamine depression of self-stimulation responding from the substantia nigra: Reversal by tricyclic antidepressants. Pharmacol. Biochem. Behav. 13:1980;379-383.
160. Kokkinidis L., McCarter B. D. Postcocaine depression and sensitization of brain-stimulation reward: Analysis of reinforcement and performance effects. Pharmacol. Biochem. Behav. 36:1990;463-471.
161. Barrett R. J., White D. K. Reward system depression following chronic amphetamine: Antagonism by haloperidol. Pharmacol. Biochem. Behav. 13:1980;555-559.
162. Cassens G., Actor C., Kling M., Schildkraut J. J. Amphetamine withdrawal: Effects on threshold of intracranial reinforcement. Psychopharmacology. 73:1981;318-322.
163. Leith N. J., Barrett R. J. Amphetamine and the reward system: Evidence for tolerance and post-drug depression. Psychopharmacology. 46:1976;19-25.
164. Simpson D. M., Annau Z. Behavioral withdrawal following several psychoactive drugs. Pharmacol. Biochem. Behav. 7:1977;59-64.
165. Wise R. A., Munn E. Withdrawal from chronic amphetamine elevates baseline intracranial self-stimulation thresholds. Psychopharmacology. 117:1995;130-136.
166. Frank R. A., Martz S., Pommering T. The effect of chronic cocaine on self-stimulation train-duration thresholds. Pharmacol. Biochem. Behav. 29:1988;755-758.
167. Schaefer G. J., Michael R. P. Changes in response rates and reinforcement thresholds for intracranial self-stimulation during morphine withdrawal. Pharmacol. Biochem. Behav. 25:1986;1263-1269.
168. Schulteis G., Markou A., Gold L. H., Stinus L., Koob G. F. Relative sensitivity of multiple indices of opiate withdrawal: A quantitative dose-response analysis. J. Pharmacol. Exp. Ther. 271:1994;1391-1398.
169. Koob G. F., Stinus L., Le Moal M., Bloom F. E. Opponent process theory of motivation: Neurobiological evidence from studies of opiate dependence. Neurosci. Biobehav. Rev. 13:1989;135-140.
170. Stinus L., Le Moal M., Koob G. F. Nucleus accumbens and amygdala are possible substrates for the aversive stimulus effects of opiate withdrawal. Neuroscience. 37:1990;767-773.
171. Mucha R. F. Is the motivational effect of opiate withdrawal reflected by common somatic indices of precipitated withdrawal? A place conditioning study in the rat. Brain Res. 418:1987;214-220.
172. Kosten T. A. Clonidine attenuates conditioned aversion produced by naloxone-precipitated opiate withdrawal. Eur. J. Pharmacol. 254:1994;59-63.
173. Markou A., Koob G. F. Postcocaine anhedonia: An animal model of cocaine withdrawal. Neuropsychopharmacology. 4:1991;17-26.
174. Dackis C. A., Gold M. S. New concepts in cocaine addiction: The dopamine depletion hypothesis. Neurosci. Biobehav. Rev. 9:1985;469-477.
175. Wise R. A. The role of reward pathways in the development of drug dependence. Pharmacol. Ther. 35:1987;227-263.
176. Wise R. A. In vivo estimates of extracellular dopamine and dopamine metabolite levels during intravenous cocaine or heroin self-administration. Semin. Neurosci. 5:1993;337-342.
177. Wise R. A., Leone P., Rivest R., Leeb K. Elevations of nucleus accumbens dopamine and DOPAC levels during intravenous heroin self-administration. Synapse. 21:1995;140-148.
178. Wise R. A., Newton P., Leeb K., Burnette B., Pocock D. J., Justice J. B. Jr. Fluctuations in nucleus accumbens dopamine concentration during intravenous cocaine self-administration in rats. Psychopharmacology. 120:1995;10-20.
179. Koob G. F., Markou A., Weiss F., Schulteis G. Opponent process and drug dependence: Neurobiological mechanisms. Semin. Neurosci. 5:1993;351-358.
180. Merlo Pich E., Lorang M., Yeganeh M., Rodríguez de Fonseca F., Raber J., Koob G. F., Weiss F. Increase in extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J. Neurosci. 15:1995;5439-5447.
181. Koob G. F. Drug addiction: The yin and yang of hedonic homeostasis. Neuron. 16:1996;893-896.
182. Davis M. The role of amygdala in fear and anxiety. Annu. Rev. Neurosci. 15:1992;353-375.
183. Le Doux J. A., Iwata J., Cicchetti P., Reis D. J. Different projections of the central amygdaloid nucleus mediate autonomic and behavioral correlates of conditioned fear. J. Neurosci. 8:1988;2517-2529.
184. Cador M., Robbins T. W., Everitt B. J. Involvement of the amygdala in stimulus-reward associations: Interaction with the ventral striatum. Neuroscience. 30:1989;77-86.
185. Everitt B. J., Cador M., Robbins T. W. Interactions between the amygdala and ventral striatum in stimulus-reward associations: Studies using a second-order schedule of sexual reinforcement. Neuroscience. 30:1989;63-75.
186. Gaffan D. Amygdala and the memory of reward. Aggleton J. P. The Amygdala: Neurobiological Aspects of Emotion. 1992;471-483 Wiley, New York.
187. Hiroi N., White N. M. The lateral nucleus of the amygdala mediates expression of the amphetamine conditioned place preference. J. Neurosci. 11:1991;2107-2116.
188. White N. M., Hiroi N. Amphetamine conditioned cue preference and the neurobiology of drug-seeking. Semin. Neurosci. 5:1993;329-336.
189. Gardner, E. L. Lepore, M. 1996, Withdrawal from a single dose of marijuana elevates baseline brain-stimulation reward thresholds in rats.
190. 9. Toxicol. Appl. Pharmacol. 32:1975;399-417.
191. Rodríguez de Fonseca, Carrera M. R. A., Navarro M., Koob G. F., Weiss F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science. 276:1997;2050-2054.
192. Cannon D. S., Carrell L. E. Rat strain differences in ethanol self-administration and taste aversion. Pharmacol. Biochem. Behav. 28:1987;57-63.
193. George F. R. Genetic and environmental factors in ethanol self-administration. Pharmacol. Biochem. Behav. 27:1987;379-384.
194. Li T. K., Lumeng L. Alcohol preference and voluntary alcohol intakes of inbred rat strains and the National Institutes of Health heterogeneous stock of rats. Alcoholism. 8:1984;485-486.
195. Ritz M. C., George F. R., deFiebre C. M., Meisch R. A. Genetic differences in the establishment of ethanol as a reinforcer. Pharmacol. Biochem. Behav. 24:1986;1089-1094.
196. Suzuki T., George F. R., Meisch R. A. Differential establishment and maintenance of oral ethanol reinforced behavior in Lewis and Fisher 344 inbred rat strains. J. Pharmacol. Exp. Ther. 245:1988;164-170.
197. Misenrendino M. J. D., Kosten T. A., Guitart X., Chi S., Nestler E. J. Individual differences in vulnerability to drug addiction: Behavioral and biochemical correlates. Soc. Neurosci. Abstr. 18:1992;1078.
198. George F. R., Meisch R. A. Oral narcotic intake as a reinforcer: Genotype × environment interaction. Behav. Genet. 14:1984;603.
199. Khodzhagel'diev T. Formirovanie vlecheniia k nikotinu u myshei linii C57Bl/6 i CBA [Development of nicotine preference in C57Bl/6 and CBA mice]. Biull. Eksp. Biol. Med. 101:1986;48-50.
200. 9. Psychopharmacology. 96:1988;365.
201. 9. Soc. Neurosci. Abstr. 15:1989;638.
202. 9in vivo. Neurosci. Lett. 129:1991;136-140.
203. Lepore M., Gardner E. L. Neurobiological relationship between vulnerability to depression and to drug abuse:In vivo. Soc. Neurosci. Abstr. 21:1995;1955.
204. Lepore M., Vorel R., Gardner E. L. Studies on the neurobiological interrelationship between vulnerability to depression and to drug abuse in animal models. Behav. Pharmacol. 6:1995;82-84.
205. Horan B., Smith M., Gardner E. L., Lepore M., Ashby C. R. Jr. (-)-Nicotine produces conditioned place preference in Lewis, but not Fischer 344 rats. Synapse. 26:1997;93-94.
206. Mechoulam R. Cannabinoids as Therapeutic Agents. 1986;CRC Press, Boca Raton.
207. Hall W., Solowij N., Lemon J. The Health and Psychological Consequences of Cannabis Use. 1994;Australian Govt. Publ. Service, Canberra.
208. Esposito R. U., Perry W., Kornetsky C. Effects ofd. Psychopharmacology. 69:1980;187-191.
209. Lorens S. A., Sainati S. M. Naloxone blocks the excitatory effect of ethanol and chlordiazepoxide on lateral hypothalamic self-stimulation behavior. Life Sci. 23:1978;1359-1364.
210. Nazzaro J. M., Seeger T. F., Gardner E. L. Naloxone blocks phencyclidine's dose-dependent effects on direct brain reward thresholds. Proceedings of World Conference on Clinical Pharmacology and Therapeutics. 1980;British Pharmacological Soc. London. p. 949.
211. Nazzaro J. M., Gardner E. L., Bridger W. H., Carlson K. R., Seeger T. F. Pentobarbital induces a naloxone-reversible decrease in mesocorticolimbic self-stimulation thresholds. Soc. Neurosci. Abstr. 7:1981;262.
212. 9. Adv. Biosci. 75:1989;671-674.
213. 9. van Ree J. M., Mulder A. H., Wiegant V. M., van Wimersma Greidanus T. B. New Leads in Opioid Research. 1990;243-245 Elsevier, Amsterdam.
214. Vaysse, P. J.-J. Gardner, E. L. Zukin, R. S. 1985, Modulation of rat brain opiate receptors by cannabinoids.
215. Vaysse P. J.-J., Gardner E. L., Zukin R. S. Modulation of rat brain opioid receptors by cannabinoids. J. Pharmacol. Exp. Ther. 241:1987;534-539.
216. 9. Eur. J. Pharmacol. 70:1981;219-224.
217. Wilson R. S., May E. L. Analgesic properties of the tetrahydrocannabinols, their metabolites, and analogs. J. Med. Chem. 18:1975;700-703.
218. 9. Eur. J. Pharmacol. 36:1976;259-262.
219. Hine B., Friedman E., Torrelio M., Gershon S. Morphine-dependent rats: Blockage of precipitated abstinence by tetrahydrocannabinol. Science. 187:1975;443-445.
220. Kumar M. S., Chen C. L. Effect of an acute dose of delta-9-THC on hypothalamic luteinizing hormone releasing hormone and met-enkephalin content and serum levels of testosterone and corticosterone in rats. Subst. Alcohol Actions/Misuse. 4:1983;37-43.
221. Ali S. F., Newport G. D., Scallet A. C., Gee K. W., Paule M. G., Brown R. M., Slikker W. Jr. Effects of chronic delta-9-tetrahydrocannabinol (THC) administration on neurotransmitter concentrations and receptor binding in the rat brain. Neurotoxicology. 10:1989;491-500.
222. Kumar A. M., Haney M., Becker T., Thompson M. L., Kream R. M., Miczek K. Effect of early exposure to Δ9-tetrahydrocannabinol on the levels of opioid peptides, gonadotropin-releasing hormone and substance P in the adult male rat brain. Brain Res. 525:1990;78-83.
223. Kumar A. M., Solomon J., Patel V., Kream R. M., Drieze J. M., Millard W. J. Early exposure to Δ9-tetrahydrocannabinol influences neuroendocrine and reproductive functions in female rats. Neuroendocrinology. 44:1986;260-264.
224. 3. Life Sci. 58:1996;1239-1247.
225. Glass M., Faull R. L. M., Dragunow M. Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience. 1998.
226. Graybiel A. M. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci. 13:1990;244-251.
227. Gerfen C. R. Synaptic organization of the striatum. J. Electron Microsc. Tech. 10:1988;265-281.
228. Voorn P., Gerfen C. P., Groenewegen H. J. Compartmental organization of the ventral striatum of the rat: Immunohistochemical distribution of enkephalin, substance P, dopamine, and calcium-binding protein. J. Comp. Neurol. 289:1989;189-201.
229. Gerfen C. P. The neostriatal mosaic: Multiple levels of compartmental organization in the basal ganglia. Annu. Rev. Neurosci. 15:1992;285-320.
230. Gerfen C. R. Functional organization of the striatum: Relevance to actions of psychostimulant drugs of abuse. Natl. Inst. Drug Abuse Res. Monogr. Ser. 125:1993;82-91.
231. Wise S. P., Murray E. A., Gerfen C. R. The frontal cortex-basal ganglia system in primates. Crit. Rev. Neurobiol. 10:1996;317-356.
232. Glass M., Brotchie J. M., Maneuf Y. P. Modulation of neurotransmission by cannabinoids in the basal ganglia. Eur. J. Neurosci. 9:1997;199-203.
233. Bidaut-Russell M., Howlett A. C. Cannabinoid receptor regulated cAMP accumulation in the rat striatum. J. Neurochem. 57:1991;1769-1773.
234. Glass M., Felder C. C. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors results in an augmentation of forskolin-stimulated cAMP in striatal neurons. Soc. Neurosci. Abstr. 22:1996;1562.
235. Le Moine C., Bloch B. D1 and D2 dopamine receptor gene expression in the rat striatum: Sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. J. Comp. Neurol. 35:1995;418-426.
236. Glass M., Dragunow M. Induction of the Krox 24 transcription factor in striosomes by a cannabinoid agonist. Neuroreport. 6:1995;241-244.
237. Glass, M. Joyce, K. Felder, C. 1996, Pertussis toxin treatment unmasks a coupling of the CB1 receptor to stimulation of cAMP accumulation.
238. s. J. Neurosci. 17:1997;5327-5333.
239. Ungerstedt U., Arbuthnott G. W. Quantitative recording of rotational behavior in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res. 24:1970;485-493.
240. Christie J. E., Crow T. J. Turning behaviour as an index of the action of amphetamines and ephedrines on central dopamine-containing neurons. Br. J. Pharmacol. 43:1971;658-667.
241. Waters D. H., Glick S. D. Asymmetrical effect of delta-9-tetrahydrocannabinol (THC) on striatal dopamine and behavior. Res. Commun. Chem. Pathol. Pharmacol. 6:1973;57-63.
242. 9. Life Sci. 37:1985;2181-2185.
243. Souilhac J., Poncelet M., Rinaldi-Carmona M., Le Fur G., Soubrié P. Intrastriatal injection of cannabinoid receptor agonists induced turning behavior in mice. Pharmacol. Biochem. Behav. 51:1995;3-7.
244. Sañudo-Peña M. C., Patrick S. L., Patrick R. L., Walker J. M. Effects of intranigral cannabinoids on rotational behavior in rats: Interactions with the dopaminergic system. Neurosci. Lett. 206:1996;21-24.
245. Rodríguez de Fonseca F., Martín Calderón J. L., Mechoulam R., Navarro M. Repeated stimulation of D1 dopamine receptors enhances (-)-11-hydroxy-delta-8-tetrahydrocannabinol-dimethyl-heptyl-induced catalepsy in male rats. Neuroreport. 5:1994;761-765.
246. Mailleux P., Verslype M., Preud'homme X., Vanderhaeghen J. J. Activation of multiple transcription factor genes by tetrahydrocannabinol in rat forebrain. Neuroreport. 5:1994;1265-1268.
247. 9. Brain Res. 710:1996;234-240.
248. 9.
249. 9. Brain Res. 621:1993;65-70.
250. 9. Soc. Neurosci. Abstr. 16:1990;1100.
251. Westerink B. H., Tuntler J., Damsma G., Rollema H., de Vries J. B. The use of tetrodotoxin for the characterization of drug-enhanced dopamine release in conscious rats studied by brain dialysis. Naunyn Schmiedeberg's Arch. Pharmacol. 336:1987;502-507.
252. Shore P. A. Actions of amfonelic acid and other non-amphetamine stimulants on the dopamine neuron. J. Pharm. Pharmacol. 28:1976;855-857.
253. Shore P. A., McMillen B. A., Miller H. H., Sanghera M. K., Kiserand R. S., German D. C. The dopamine neuronal storage system and non-amphetamine psychotogenic stimulants: A model for psychosis. Usdin E., Kopin I. J., Barchas J. Catecholamines: Basic and Clinical Frontiers. 1979;722-735 Pergamon Press, New York.
254. Fuller R. W., Snoddy H. D. Effect of mazindol on brain dopamine turnover in spiperone-treated rats. J. Neural Transm. 44:1979;13-19.
255. 9in vivo. Natl. Inst. Drug Abuse Res. Monogr. Ser. 141:1994;312.
256. Wood P. L., Altar C. A. Dopamine release in vivo from nigrostriatal, mesolimbic, and mesocortical neurons: Utility of 3-methoxytyramine measurements. Pharmacol. Rev. 40:1988;163-187.
257. Heal D. J., Frankland A. T. J., Buckett W. R. A new and highly sensitive method for measuring 3-methoxytyramine using HPLC with electrochemical detection: Studies with drugs which alter dopamine metabolism in the brain. Neuropharmacology. 29:1990;1141-1150.
258. 14. Neuropharmacology. 13:1974;1109-1114.
259. Johnson K. M., Dewey W. L., Harris L. S. Some structural requirements for inhibition of high-affinity synaptosomal serotonin uptake by cannabinoids. Mol. Pharmacol. 12:1976;345-352.
260. Hershkowitz M., Goldman R., Raz A. Effect of cannabinoids on neurotransmitter uptake, ATPase activity and morphology of mouse brain synaptosomes. Biochem. Pharmacol. 26:1977;1327-1331.
261. 1. Eur. J. Pharmacol. 59:1979;267-276.
262. Galzin A. M., Dubocovich M. L., Langer S. Z. Presynaptic inhibition of dopamine receptor agonists of noradrenergic neurotransmission in the rabbit hypothalamus. J. Pharmacol. Exp. Ther. 221:1982;461-471.
263. Langer S. Z., Moret C. Citalopram antagonizes the stimulation by lysergic acid diethylamide of presynaptic inhibitory serotonin autoreceptors in the rat hypothalamus. J. Pharmacol. Exp. Ther. 222:1982;220-226.
264. Cubeddu L. X., Hoffmann I. S., James M. K. Frequency-dependent effects of neuronal uptake inhibitors on the autoreceptor-mediated modulation of dopamine and acetylcholine release from the rabbit striatum. J. Pharmacol. Exp. Ther. 226:1983;88-94.
265. Göthert M., Schliker E., Kostermann F. Relationship between transmitter uptake inhibition and effects of α-adrenoreceptor agonists on serotonin and noradrenaline release in the rat brain cortex. Naunyn-Schmiedeberg's Arch. Pharmacol. 322:1983;121-128.
266. Galzin A. M., Moret C., Verzier B., Langer S. Z. Interaction between tricyclic and nontricyclic 5-hydroxytryptamine uptake inhibitor and the presynaptic 5-hydroxytryptamine inhibitory autoreceptors in the rat hypothalamus. J. Pharmacol. Exp. Ther. 235:1985;200-211.
267. Moret C., Briley M. Sensitivity of the response of 5-HT autoreceptors to drugs modifying synaptic availability of 5-HT. Neuropharmacology. 27:1988;43-49.
268. Gintzler A. R., Xu H. Different G proteins mediate the opioid inhibition or enhancement of evoked [5-methionine]enkephalin release. Proc. Natl. Acad. Sci. USA. 88:1991;4741-4745.
269. 9. Science. 175:1972;911-912.
270. Kay J. Aversive effects of repeated injections of THC in rats. Psychol. Rep. 14:1975;89-92.
271. Fischer G. J., Vail B. J. Preexposure to delta-9-THC blocks THC-induced conditioned taste aversion in rats. Behav. Neural Biol. 30:1980;191-196.
272. 9. Psychopharmacology. 74:1981;149-157.
273. Parker L. A., Gillies T. THC-induced place and taste aversions in Lewis and Sprague-Dawley rats. Behav. Neurosci. 109:1995;71-78.
274. McGregor I. S., Issakidis C. N., Prior G. Aversive effects of the synthetic cannabinoid CP 55,940 in rats. Pharmacol. Biochem. Behav. 53:1996;657-664.
275. Reicher M., Holman E. Location preference and flavor aversion reinforced by amphetamine in rats. Anim. Learn. Behav. 5:1977;343-346.
276. Wise R. A., Yokel R. A., DeWit H. Both positive reinforcement and conditioned aversion from amphetamine and from apomorphine in rats. Science. 191:1976;1273-1275.
277. White N., Sklar L., Amit Z. The reinforcing action of morphine and its paradoxical side effect. Psychopharmacology. 52:1977;63-66.
278. van der Kooy D. Place conditioning: A simple and effective method for assessing the motivational properties of drugs. Bozarth M. A. Methods for Assessing the Reinforcing Properties of Abused Drugs. 1987;229-240 Springer-Verlag, New York.
279. Goett J. M., Kay E. J. Lithium chloride and delta-9-THC lead to conditioned aversions in the pigeon. Psychopharmacology. 72:1981;215-216.
280. Sañudo-Peña M. C., Tsou K., Delay E. R., Hohman A. G., Force M., Walker J. M. Endogenous cannabinoids as an aversive or counter-rewarding system in the rat. Neurosci. Lett. 223:1997;125-128.
281. 9.
282. 9. Life Sci. 56:1995;2073-2080.
283. Fudala P. J., Teoh K. W., Iwamoto E. T. Pharmacologic characterization of nicotine-induced conditioned place preference. Pharmacol. Biochem. Behav. 22:1985;237-241.
284. Jorenby D. E., Steinpreis R. E., Sherman J. E., Baker T. B. Aversion instead of preference learning indicated by nicotine place conditioning in rats. Psychopharmacology. 101:1990;533-538.
285. Fudala P. J., Iwamoto E. T. Conditioned aversion after delay place conditioning with amphetamine. Pharmacol. Biochem. Behav. 35:1990;89-92.
286. Noyes J. R., Brunk S. F., Avery D. H., Canter A. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin. Pharmacol. Ther. 18:1975;84-89.
287. Raft D., Gregg J., Ghia J., Harris L. Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Psychological correlate of the analgesic response. Clin. Pharmacol. Ther. 21:1977;26-33.
288. Laszlo J., Lucas V. S., Hanson D. C., Cronin C. M., Sallan S. E. Levonantradol for chemotherapy-induced emesis: Phase I-II oral administration. J. Clin. Pharmacol. 21:1981;51S-56S.
289. 9. Life Sci. 56:1995;2169-2176.
290. Bloch E., Thysen B., Morrill G. A., Gardner E., Fujimoto G. Effects of cannabinoids on reproduction and development. Vitam. Horm. 36:1978;203-258.
291. Sieber B., Frischknecht H. R., Waser P. G. Behavioral effects of hashish in mice. IV. Social dominance, food dominance, and sexual behavior within a group of males. Psychopharmacology. 73:1981;142-146.
292. Turley W. A. Jr., Floody A. R. Δ-9-Tetrahydrocannabinol stimulates receptive and proceptive sexual behaviors in female hamsters. Pharmacol. Biochem. Behav. 14:1981;745-747.
293. Cutler M. G., Mackintosh J. H. Cannabis and delta-9-tetrahydrocannabinol. Effects on elements of social behaviour in mice. Neuropharmacology. 23:1984;1091-1097.
294. McGivern R. F., Handa R. J. Prenatal exposure to drugs of abuse: Methodological considerations and effects on sexual differentiation. Natl. Inst. Drug Abuse Res. Monogr. Ser. 164:1996;78-124.
295. 9. Psychopharmacology. 116:1994;414-422.
296. Sofia R. D., Knoblock L. C. Comparative effects of various naturally occurring cannabinoids on food, sucrose and water consumption by rats. Pharmacol. Biochem. Behav. 4:1976;591-599.
297. Brown J. E., Kassouny M., Cross J. K. Kinetic studies of food intake and sucrose solution preference by rats treated with low doses of delta-9-tetrahydrocannabinol. Behav. Biol. 20:1977;104-110.
298. Milano W. C., Wild K. D., Hui Y. Z., Hubbell C. L., Reid L. D. PCP, THC, ethanol, and morphine and consumption of palatable solutions. Pharmacol. Biochem. Behav. 31:1988;893-897.
299. McGregor, I. S. Saharov, T. Dielenberg, R. A. Arnold, J. C. Booker, S. L. Topple, A. N. 1997, The effects of cannabinoids on beer and sucrose consumption in rats.
300. Arnone M., Maruani J., Chaperon F., Thiébot M.-H., Poncelot M., Soubrié P., Le Fur G. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology. 132:1997;104-106.
301. 9. Psychopharmacology. 103:1991;172-176.
302. Kaymakçalan S. Physiology and psychological dependence on THC in rhesus monkeys. Paton W. D. M., Crown J. Cannabis and Its Derivatives. 1972;142-149 Oxford Univ. Press, London.
303. Corcoran M. E., Amit Z. Reluctance of rats to drink hashish suspensions: Free-choice and forced consumption, and the effects of hypothalamic stimulation. Psychopharmacologia. 35:1974;129-147.
304. Leite J. R., Carlini E. A. Failure to obtain "cannabis directed behavior" and abstinence syndrome in rats chronically treated with cannabis sativa extracts. Psychopharmacologia. 36:1974;133-145.
305. 9. Psychopharmacologia. 37:1974;23-29.
306. Carney J. M., Uwaydah I. M., Balster R. L. Evaluation of a suspension system for intravenous self-administration of water insoluble substances in the rhesus monkey. Pharmacol. Biochem. Behav. 7:1977;357-364.
307. Takahashi R. N., Singer G. Cross self-administration of delta 9-tetrahydrocannabinol andD. Braz. J. Med. Biol. Res. 14:1981;395-400.
308. Pickens R., Thompson T., Muchow D. C. Cannabis and phencyclidine self-administered by animals. Goldfarb L., Hoffmeister F. Psychic Dependence. 1973;78-86 Springer-Verlag, Berlin.
309. 9. Pharmacologist. 13:1971;246.
310. 9. Pharmacol. Biochem. Behav. 11:1979;737-740.
311. Takahashi R. N., Singer G. Effects of body weight levels on cannabis self-administration. Pharmacol. Biochem. Behav. 13:1980;877-881.
312. Onaivi E. S., Green M. R., Martin B. R. Pharmacological characterization of cannabinoids in the elevated plus-maze. J. Pharmacol. Exp. Ther. 253:1990;1002-1009.
313. 1221,38α37. J. Pharmacol. Exp. Ther. 276:1996;56-64.
314. Fratta W., Martellotta M. C., Cossu G., Fattore L. WIN 55,212-2 induces intravenous self-administration in drug-naive mice. Soc. Neurosci. Abstr. 23:1997;1869.